- Telehealth Visits
- Insurance plan information
Ashlie Browning, MS
She | Her | HersCancer Genetics • Genetic Counselor- Telehealth Visits
- Insurance plan information
Ashlie Browning, MS
She | Her | HersCancer Genetics • Genetic Counselor- Telehealth Visits
- Insurance plan information
On this page
About me
Ashlie Browning is a genetic counselor who cares for patients with cancer or a family history of cancer. She helps patients and families understand their cancer risk, offers genetic testing options and makes cancer screening recommendations. Her goal is to ensure all patients receive personalized, empathetic care.
Browning has a special interest in pancreatic cancer and is a member of the UCSF Pancreatic Cancer Case Conference. She is active in the Pancreatic Cancer Early Detection (PRECEDE) Consortium, an international collaboration to improve prevention and detection of pancreatic cancer.
After earning a bachelor's degree in biology, with a concentration in molecular and cellular biology, at California Polytechnic State University (Cal Poly), Browning earned her master's degree in genetic counseling from the University of Utah. Before joining UCSF, she provided genetic counseling at two other highly regarded cancer treatment centers.
Education & training
Board certification
- Certified Genetic Counselor, American Board of Genetic Counseling
Degree
- MS, University of Utah
My expertise
Specialties
- Cancer Genetics
- Genetic Counselor
Conditions
- Cancer
Locations
Clinical Trials query: q=health_gateway_id_ss%3A%28%223313%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%223313%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Publication%22
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.